TrialAnnals of oncology : official journal of the European Society for Medical Oncology2015

A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial.

C S Fuchs et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.